Replimune Group, Inc.

NasdaqGS REPL

Replimune Group, Inc. Price to Book Ratio (P/B) on January 14, 2025: 2.01

Replimune Group, Inc. Price to Book Ratio (P/B) is 2.01 on January 14, 2025, a 88.52% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Replimune Group, Inc. 52-week high Price to Book Ratio (P/B) is 2.87 on November 22, 2024, which is 42.33% above the current Price to Book Ratio (P/B).
Replimune Group, Inc. 52-week low Price to Book Ratio (P/B) is 0.68 on May 29, 2024, which is -66.27% below the current Price to Book Ratio (P/B).
Replimune Group, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.51.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: REPL

Replimune Group, Inc.

CEO	Dr. Sushil Patel Ph.D.
IPO Date	July 20, 2018
Location	United States
Headquarters	500 Unicorn Park Drive
Employees	331
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years